Ginkgo Bioworks is a biotechnology company that focuses on the design and engineering of microbial strains for various applications across diverse industries, including pharmaceuticals, agriculture, and industrial biotechnology
By leveraging advanced genetic engineering and synthetic biology techniques, Ginkgo aims to create custom organisms that can produce valuable ingredients, enhance agricultural yields, or contribute to sustainable manufacturing processes. The company operates through a platform model, allowing collaborations with partners to transform biological systems into efficient and scalable solutions that address real-world challenges, all while paving the way for a future with more sustainable and tailored biological products.
Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery by leveraging AI and proprietary biological data, offering affordable and accessible tools for researchers.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud.
DNA stock results show that Ginkgo Bioworks Holdings missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
